{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:34:39Z","timestamp":1761755679757,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ajp.2016.10.005","type":"journal-article","created":{"date-parts":[[2016,10,16]],"date-time":"2016-10-16T06:46:05Z","timestamp":1476600365000},"page":"36-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series"],"prefix":"10.1016","volume":"25","author":[{"given":"Keiko","family":"Naono-Nagatomo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Naono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichiro","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Funahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Uchimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2016.10.005_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brainres.2003.09.082","article-title":"The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release","volume":"1003","author":"Aihara","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.ajp.2016.10.005_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/898013","article-title":"Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia","volume":"2011","author":"Barak","year":"2011","journal-title":"J. Obes."},{"key":"10.1016\/j.ajp.2016.10.005_bib0015","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1365-2753.2007.00921.x","article-title":"The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use","volume":"14","author":"Berk","year":"2008","journal-title":"J. Eval. Clin. Pract."},{"key":"10.1016\/j.ajp.2016.10.005_bib0020","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","article-title":"Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study","volume":"107","author":"Byerly","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2016.10.005_bib0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ajp.2016.10.005_bib0030","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ajp.2016.10.005_bib0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/jpm.2008.9690","article-title":"Study design, precision, and validity in observational studies","volume":"12","author":"Carlson","year":"2009","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.ajp.2016.10.005_bib0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1440-1819.2010.02156.x","article-title":"Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series","volume":"65","author":"Chen","year":"2011","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ajp.2016.10.005_bib0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"58","author":"Chen","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ajp.2016.10.005_bib0050","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1017\/S1461145709009948","article-title":"Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects","volume":"12","author":"Han","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2016.10.005_bib0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0269881107087951","article-title":"Medical causes and consequences of hyperprolactinemia: a context for psychiatrists","volume":"22","author":"Holt","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2016.10.005_bib0060","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","article-title":"A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2016.10.005_bib0065","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2016.10.005_bib0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/WNF.0000000000000006","article-title":"Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series","volume":"36","author":"Kawabe","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ajp.2016.10.005_bib0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pnpbp.2011.11.016","article-title":"Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics: prog","volume":"37","author":"Kikuchi","year":"2012","journal-title":"Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ajp.2016.10.005_bib0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/WNF.0b013e31819a68b5","article-title":"Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia","volume":"32","author":"Kim","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ajp.2016.10.005_bib0085","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-012-2953-0","article-title":"The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory: a dual [(11)C] raclopride and [(18)F]FDG imaging study with aripiprazole","volume":"227","author":"Kim","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ajp.2016.10.005_bib0090","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","article-title":"Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole","volume":"32","author":"Lu","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ajp.2016.10.005_bib0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2016.10.005_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5234\/cnpt.1.1","article-title":"Improvement in antipsychotic-induced hyperprolactinemia with the addition of aripiprazole in schizophrenic patients","volume":"1","author":"Mihara","year":"2010","journal-title":"Clin. Neuropsychopharmacol. Ther."},{"key":"10.1016\/j.ajp.2016.10.005_bib0105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4088\/JCP.15l09920","article-title":"An open-label, pilot trial of adjunctive tocilizumab in schizophrenia","volume":"77","author":"Miller","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2016.10.005_bib0110","first-page":"549","article-title":"Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia","volume":"11","author":"Ranjbar","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ajp.2016.10.005_bib0115","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fnbeh.2015.00322","article-title":"Comparison of visuospatial and verbal abilities in first psychotic episode of schizophrenia spectrum disorder: impact on global functioning and quality of life","volume":"9","author":"Rodriguez","year":"2015","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.ajp.2016.10.005_bib0120","doi-asserted-by":"crossref","first-page":"970","DOI":"10.4088\/JCP.v68n0624a","article-title":"Schizophrenia symptoms remain stable during decreases from 2 antipsychotics to aripiprazole","volume":"68","author":"Salzman","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2016.10.005_bib0125","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2016.10.005_bib0130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1440-1819.2009.02036.x","article-title":"Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study","volume":"64","author":"Takeuchi","year":"2010","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ajp.2016.10.005_bib0135","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archpsyc.59.12.1147","article-title":"Dopamine antagonists and the development of breast cancer","volume":"59","author":"Wang","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ajp.2016.10.005_bib0140","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","author":"Yasui-Furukori","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2016.10.005_bib0145","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacology"}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201816301204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201816301204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:30:34Z","timestamp":1761755434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201816301204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":29,"alternative-id":["S1876201816301204"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2016.10.005","relation":{},"ISSN":["1876-2018"],"issn-type":[{"type":"print","value":"1876-2018"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2016.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}